Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 114.97 Billion KRW | 6.75% |
| 2022 | 107.7 Billion KRW | 2.98% |
| 2021 | 104.58 Billion KRW | -16.81% |
| 2020 | 125.71 Billion KRW | -4.56% |
| 2019 | 131.73 Billion KRW | -6.04% |
| 2018 | 140.19 Billion KRW | 12.89% |
| 2017 | 124.18 Billion KRW | -0.96% |
| 2016 | 125.38 Billion KRW | 1.02% |
| 2015 | 124.11 Billion KRW | -7.56% |
| 2014 | 134.26 Billion KRW | 5.64% |
| 2013 | 127.09 Billion KRW | -4.9% |
| 2012 | 133.63 Billion KRW | 7.27% |
| 2011 | 124.57 Billion KRW | -2.33% |
| 2010 | 127.54 Billion KRW | -0.28% |
| 2009 | 127.9 Billion KRW | 2.68% |
| 2008 | 124.56 Billion KRW | 20.45% |
| 2007 | 103.41 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 122.76 Billion KRW | 3.91% |
| 2024 Q1 | 118.14 Billion KRW | 2.76% |
| 2023 Q4 | 114.97 Billion KRW | -4.35% |
| 2023 Q3 | 120.2 Billion KRW | 6.72% |
| 2023 FY | 114.97 Billion KRW | 6.75% |
| 2023 Q2 | 112.64 Billion KRW | 3.4% |
| 2023 Q1 | 108.93 Billion KRW | 1.15% |
| 2022 Q2 | 107.98 Billion KRW | -0.99% |
| 2022 Q1 | 109.06 Billion KRW | 4.29% |
| 2022 FY | 107.7 Billion KRW | 2.98% |
| 2022 Q4 | 107.7 Billion KRW | -0.13% |
| 2022 Q3 | 107.84 Billion KRW | -0.14% |
| 2021 Q1 | 121.81 Billion KRW | -3.1% |
| 2021 Q3 | 111.42 Billion KRW | 3.34% |
| 2021 Q4 | 104.58 Billion KRW | -6.14% |
| 2021 FY | 104.58 Billion KRW | -16.81% |
| 2021 Q2 | 107.82 Billion KRW | -11.48% |
| 2020 Q1 | 134.38 Billion KRW | 2.02% |
| 2020 FY | 125.71 Billion KRW | -4.56% |
| 2020 Q2 | 134.86 Billion KRW | 0.35% |
| 2020 Q4 | 125.71 Billion KRW | -5.86% |
| 2020 Q3 | 133.54 Billion KRW | -0.98% |
| 2019 Q2 | 140.84 Billion KRW | -0.56% |
| 2019 Q3 | 142.27 Billion KRW | 1.02% |
| 2019 Q4 | 131.73 Billion KRW | -7.41% |
| 2019 FY | 131.73 Billion KRW | -6.04% |
| 2019 Q1 | 141.63 Billion KRW | 1.02% |
| 2018 Q4 | 140.19 Billion KRW | -9.51% |
| 2018 Q1 | 124.65 Billion KRW | 0.38% |
| 2018 FY | 140.19 Billion KRW | 12.89% |
| 2018 Q2 | 142.76 Billion KRW | 14.52% |
| 2018 Q3 | 154.92 Billion KRW | 8.52% |
| 2017 Q2 | 125.07 Billion KRW | 2.75% |
| 2017 Q4 | 124.18 Billion KRW | -2.07% |
| 2017 FY | 124.18 Billion KRW | -0.96% |
| 2017 Q3 | 126.8 Billion KRW | 1.39% |
| 2017 Q1 | 121.72 Billion KRW | -2.92% |
| 2016 Q3 | 127.28 Billion KRW | 0.45% |
| 2016 Q4 | 125.38 Billion KRW | -1.49% |
| 2016 Q1 | 125.93 Billion KRW | 1.47% |
| 2016 FY | 125.38 Billion KRW | 1.02% |
| 2016 Q2 | 126.71 Billion KRW | 0.62% |
| 2015 Q1 | 134.48 Billion KRW | 0.17% |
| 2015 Q4 | 124.11 Billion KRW | -6.53% |
| 2015 Q3 | 132.79 Billion KRW | -1.43% |
| 2015 FY | 124.11 Billion KRW | -7.56% |
| 2015 Q2 | 134.71 Billion KRW | 0.17% |
| 2014 Q2 | 127.36 Billion KRW | 0.22% |
| 2014 FY | 134.26 Billion KRW | 5.64% |
| 2014 Q4 | 134.26 Billion KRW | -2.04% |
| 2014 Q3 | 137.06 Billion KRW | 7.62% |
| 2014 Q1 | 127.07 Billion KRW | -0.01% |
| 2013 Q3 | 131.84 Billion KRW | -1.04% |
| 2013 Q4 | 127.09 Billion KRW | -3.61% |
| 2013 FY | 127.09 Billion KRW | -4.9% |
| 2013 Q2 | 133.22 Billion KRW | -0.64% |
| 2013 Q1 | 134.08 Billion KRW | 0.34% |
| 2012 Q1 | 133.11 Billion KRW | 0.0% |
| 2012 FY | 133.63 Billion KRW | 7.27% |
| 2012 Q4 | 133.63 Billion KRW | -2.4% |
| 2012 Q3 | 136.92 Billion KRW | -0.51% |
| 2012 Q2 | 137.62 Billion KRW | 3.39% |
| 2011 FY | 124.57 Billion KRW | -2.33% |
| 2011 Q3 | 128.06 Billion KRW | 2.63% |
| 2011 Q2 | 124.78 Billion KRW | -3.12% |
| 2011 Q1 | 128.8 Billion KRW | 0.99% |
| 2010 Q1 | 132.63 Billion KRW | 3.7% |
| 2010 FY | 127.54 Billion KRW | -0.28% |
| 2010 Q4 | 127.54 Billion KRW | -8.06% |
| 2010 Q3 | 138.72 Billion KRW | 2.07% |
| 2010 Q2 | 135.91 Billion KRW | 2.47% |
| 2009 Q4 | 127.9 Billion KRW | 1.14% |
| 2009 FY | 127.9 Billion KRW | 2.68% |
| 2009 Q2 | 129.73 Billion KRW | 3.17% |
| 2009 Q1 | 125.75 Billion KRW | 0.95% |
| 2009 Q3 | 126.45 Billion KRW | -2.52% |
| 2008 Q1 | 103.1 Billion KRW | -0.31% |
| 2008 Q3 | 102.13 Billion KRW | -1.69% |
| 2008 FY | 124.56 Billion KRW | 20.45% |
| 2008 Q4 | 124.56 Billion KRW | 21.97% |
| 2008 Q2 | 103.88 Billion KRW | 0.76% |
| 2007 Q1 | 100.86 Billion KRW | 0.0% |
| 2007 Q3 | 104.36 Billion KRW | 0.04% |
| 2007 Q2 | 104.32 Billion KRW | 3.43% |
| 2007 FY | 103.41 Billion KRW | 0.0% |
| 2007 Q4 | 103.41 Billion KRW | -0.91% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 41.995% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 94.125% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 86.89% |
| HANDOK Inc. | 790.33 Billion KRW | 85.453% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | 32.614% |
| Yuhan Corporation | 2814.07 Billion KRW | 95.914% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 91.258% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -22.994% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 94.11% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 52.044% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 75.48% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 51.396% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 66.998% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 41.995% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 72.573% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 76.995% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 80.493% |
| JW Holdings Corporation | 1176.26 Billion KRW | 90.226% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 81.191% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 91.802% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 82.176% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 67.158% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | 25.362% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 68.983% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 76.407% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 41.995% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 89.335% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 93.505% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 82.176% |
| Yuhan Corporation | 2814.07 Billion KRW | 95.914% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 86.935% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | 49.262% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 88.43% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 82.176% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 72.619% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 75.478% |
| CKD Bio Corp. | 293.78 Billion KRW | 60.865% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 77.367% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 79.65% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 71.345% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 67.158% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 92.104% |
| Boryung Corporation | 922.36 Billion KRW | 87.535% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 74.015% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 75.48% |
| JW Lifescience Corporation | 255.83 Billion KRW | 55.06% |